NEW YORK, June 2, 2023 /PRNewswire/ — Terran Biosciences, Inc. (“Terran”), a CNS-focused biotech platform company, has entered into an agreement with French pharmaceutical company Pierre Fabre Médicament S.A.S (“Pierre Fabre”) for worldwide exclusive rights to develop and commercialize a pipeline of Pierre Fabre’s assets to treat neuropsychiatric illnesses. The deal features the novel lead…

Source

Previous articleNuminus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023
Next articlePsychedelics Weekly – Drug Testing and Harm Reduction, Ketamine vs. ECT, and Does Therapy Really Work?